1. Introduction {#sec1-vetsci-07-00055}
===============

Pancreatic neoplasms are rare in cats, dogs \[[@B1-vetsci-07-00055],[@B2-vetsci-07-00055],[@B3-vetsci-07-00055]\], and humans \[[@B4-vetsci-07-00055]\]. Carcinoma is the most common tumor type in cats and dogs, but adenomas, sarcomas, lymphomas, unclassified tumors, and metastatic neoplasms have also been described \[[@B1-vetsci-07-00055],[@B2-vetsci-07-00055],[@B3-vetsci-07-00055],[@B5-vetsci-07-00055]\]. Pancreatic neoplasms generally cause non-specific constitutional and gastrointestinal signs such as lethargy, anorexia, weight loss, diarrhea, vomiting, abdominal pain, or palpable abdominal masses \[[@B6-vetsci-07-00055],[@B7-vetsci-07-00055],[@B8-vetsci-07-00055]\].

Lymphomas are common neoplasms in most domestic species. Gastrointestinal lymphoma is the most common form of lymphoma in cats and is associated with clinical presentation such as weight loss, vomiting, diarrhea anorexia, and lethargy \[[@B9-vetsci-07-00055]\]. However, pancreatic involvement has been reported in only some cases and pancreas-specific blood parameters were not included in the studies \[[@B10-vetsci-07-00055],[@B11-vetsci-07-00055],[@B12-vetsci-07-00055],[@B13-vetsci-07-00055]\]. While retroviral diseases (feline leukemia virus (FeLV) and feline immunodeficiency virus) are risk factors, a high number of cats with alimentary lymphomas have been reported to be virus negative \[[@B14-vetsci-07-00055]\].

As a mutant of FeLV, the feline sarcomavirus can cause sarcomas in cats \[[@B15-vetsci-07-00055]\], but literature about feline pancreatic sarcomas is scant. There is one case report of a feline primary pancreatic carcinosarcoma with metastases in uterus, omentum, and diaphragm \[[@B16-vetsci-07-00055]\]. Mesenchymal pancreatic tumors in humans are reported to have a poor prognosis with a median overall survival time of 21 months \[[@B17-vetsci-07-00055],[@B18-vetsci-07-00055]\]. Visceral hemangiosarcomas are a common neoplasm in dogs, especially German Shepherds, but are uncommon in cats \[[@B19-vetsci-07-00055]\]. Hemangiosarcomas in dogs often occur in the spleen and the right atrium \[[@B19-vetsci-07-00055]\]. In cats, they arise mostly in liver, intestine, lymph nodes, or spleen \[[@B20-vetsci-07-00055]\]. The prognosis is poor in both dogs and cats \[[@B19-vetsci-07-00055],[@B20-vetsci-07-00055],[@B21-vetsci-07-00055]\].

The aim of this study is to characterize 17 cases of feline non-epithelial pancreatic tumors including clinical data, histopathology, and immunohistochemistry.

2. Materials and Methods {#sec2-vetsci-07-00055}
========================

During the 2011--2018 period, 571 feline pancreatic tissue samples, submitted routinely to LABOKLIN GmbH & Co. KG (Bad Kissingen, Germany), were investigated. From these, 540 showed representative sample size and adequate tissue preservation. Included into this study were mesenchymal tumors within the pancreas, like spindle and round cell tumors from 17 cats. Excluded were samples without (n = 31), other tumors such as primary exocrine neoplasms (21/540 adenomas, 54/540 carcinomas) or endocrine tumors (2/540), as well as tumor-like lesions like nodular hyperplasia.

The age of the cats was one to 17 years (median 12). Ten cats were male (1 entire, 9 neutered) and seven female (3 entire, 4 spayed). The breeds were Domestic Shorthair (DSH, n = 12), British Longhair (n = 1), British Shorthair (n = 1), Carthusian (n = 1), Siamese (n = 1), and Sacred Birman (n = 1).

Complete pancreas (n = 4), fully excised tumor masses (n = 4) and excisional biopsies (n = 9) of the pancreas were examined. The samples were measured and inspected macroscopically in detail with respect to size, cut surface, and color. This study refers to size of the complete neoplasm unless specified otherwise. Representative sites were prepared for routine histopathological examination and embedded in paraffin according to standard procedures. Slides were routinely stained with hematoxylin-eosin (HE) and Giemsa. Tumors were evaluated according to the world health organization (WHO) classification of mesenchymal \[[@B22-vetsci-07-00055],[@B23-vetsci-07-00055],[@B24-vetsci-07-00055]\] and hematopoietic tumors \[[@B25-vetsci-07-00055]\]. Mitotic figures were counted within 10 high power fields (HPF) by 400 x microscope objective (visual field: 68,700 µm²) in areas of the highest mitotic activity and were reported as mean value/HPF. Lymphomas were graded as low grade: \<5 mitotic figures/HPF, intermediate grade: 5--10 mitotic figures/HPF and high grade: \>10 mitotic figures/HPF \[[@B26-vetsci-07-00055]\]. Pancreatitis was classified according to De Cock et al. \[[@B27-vetsci-07-00055]\].

The immunohistochemical panel of primary antibodies used and their dilution are listed in [Table 1](#vetsci-07-00055-t001){ref-type="table"}. The two antibodies for FeLV (gp70 and p27) were diluted appropriately and consequently mixed at a ratio of 1:1 for further procedure. Pre-treatment included peroxidase blocking with 0.66% hydrogen peroxidase for all markers. Afterwards, the slides were heated either in 1:10 diluted HIER T-EDTA buffer pH 9.0 (10×) (Zytomed Systems GmbH, Berlin, Germany, 2VCO29-500) in a steam cooker (vimentin, desmin, CD31, CD3, CD79a, CD117/c-kit, FeLV), or in 1:10 diluted target retrieval solution pH 6.0 (10×) (Dako, Glostrup, Denmark, S1699) in a pressure cooker (smooth muscle actin, von Willebrand factor (vWF)). Dako EnVision+ System-HPR for mouse or rabbit primary antibodies (Dako, Glostrup, Denmark, K4006 or K4010) with 3,3'-diaminobenzine (DAB) was used for immunohistochemical staining. Counterstaining was done with Meyer's hematoxylin (Bio-Optica Milano S.p.A., Milano, Italy, BIO 05-06002/CO). Slides of the same organs prepared with normal mouse IgG (Dako, Glostrup, Denmark, X0931) or rabbit IgG (Dako, Glostrup, Denmark, X0936), with the same dilution as the specific reagents, were used as negative control. Positive controls varied for the different antibodies: tissue with fibrocytes and fibroblasts for vimentin, intestine for smooth muscle actin, muscle tissue for desmin, vessel rich tissue for vWF and CD31, lymph nodes for CD3 and CD79a, skin tissue with mast cells for CD117/c-kit, and PCR positive spleen tissue for FeLV.

Clinicopathologic data were available for six cats (five lymphomas and one sarcoma). The serum samples in these cases were taken shortly before or during surgery. Alpha-amylase (reference interval: \<1850 U/L), 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6′-methylresorufin) ester (DGGR) lipase (reference interval: \<26 U/L) and serum amyloid A (SAA, reference interval: \<6.7 µg/mL) were examined with cobas e602 or cobas c701 analyzer (Roche Diagnostics, Mannheim, Germany). Feline pancreatic lipase immunoreactivity (fPLI, reference interval: \<3.5 µg/L, questionable: 3.5--5.4 µg/L, indicative for pancreatitis: \>5.4 µg/L) and feline trypsin-like immunoreactivity (fTLI, reference interval: 12--82 µg/L, indicative for pancreatitis \>100 µg/L) values were determined by an ELISA assay at LABOKLIN GmbH & Co. KG.

3. Results {#sec3-vetsci-07-00055}
==========

In pancreatic tissue from 17 cats, round (n = 13) and spindle (n = 4) cell tumors were diagnosed histopathologically ([Table 2](#vetsci-07-00055-t002){ref-type="table"}). Round cell tumors included 12 lymphomas and one mast cell tumor. Spindle cell tumors were classified as two hemangiosarcomas, one pleomorphic sarcoma, and one fibrosarcoma. Clinical pathology was available for five cats with lymphoma and one cat with pleomorphic sarcoma ([Table 3](#vetsci-07-00055-t003){ref-type="table"}).

3.1. Round Cell Tumors, n = 13 {#sec3dot1-vetsci-07-00055}
------------------------------

### 3.1.1. Lymphoma, n = 12 {#sec3dot1dot1-vetsci-07-00055}

Cats with lymphomas were one to 16 years old (median 11) and predominantly male (75.0%). The majority of cats were Domestic Shorthair (66.7%) ([Table 2](#vetsci-07-00055-t002){ref-type="table"}). Clinical reports were available for 9 out of 12 cats: The cats showed vomiting (n = 3), lethargy (n = 3), inappetence (n = 3), diarrhea (n = 2), painful abdomen (n = 2), ascites (n = 2), palpable abdominal mass (n = 1), and seizures (n = 1). Clinical pathology results were available for five cats ([Table 3](#vetsci-07-00055-t003){ref-type="table"}). The fPLI values were increased in all cats (5/5) and SAA values were high in four out of five cats. DGGR lipase values were increased in three out of five cases. Alpha-amylase and fTLI were within the reference range in all cats (5/5). A complete blood count (CBC) was available for three cats: leukocytosis was present in all animals, but lymphocytosis with severe leukocytosis and neutrophilia only in one cat (No. 7). One 10-year-old British Shorthair (No. 3) showed lymphopenia.

The macroscopic appearance of pancreatic tissues varied from normal to diffusely enlarged with fine granulated texture ([Figure 1](#vetsci-07-00055-f001){ref-type="fig"}A). Masses varied in size from 0.3 × 0.3 × 0.3 to 4.0 × 4.0 × 4.0 cm. Histopathologically, ten cats with lymphoma showed additional involvement of the intestine (n = 6), lymph node (mesenteric, n = 3; unknown location, n = 1), adipose tissue (mesenteric, n = 2; peripancreatic, n = 1), liver (n = 2), omentum (n = 2), stomach (n = 1), spleen (n = 1) or kidney (n = 1). Histologically, neoplastic lymphocytes infiltrated the pancreas multifocally. Neoplastic cells were small (n = 1), intermediate (n = 4), or large (n = 7) sized. In contrast to lymphoplasmacytic pancreatitis, the tumor cell population was monomorphic, with varying degrees of nuclear atypia and mitotic activity. Lymphomas were graded as low (n = 9), intermediate (n = 2), or high (n = 1) grade. In seven out of 12 cases, an additional mild purulent (n = 3), mild lymphoplasmacytic (n = 2) or marked purulent (n = 2) pancreatitis was present.

Lymphoma was diagnosed in most of the cases (11/12) with the standard staining (HE). However, case No. 12 showed undifferentiated malignant neoplasia and immunohistochemistry was necessary for the diagnosis. Immunohistochemically, lymphomas were classified as T-cell (n = 9, [Figure 1](#vetsci-07-00055-f001){ref-type="fig"}B) or B-cell (n = 3) lymphoma. In two cats with T-cell lymphoma (Nos. 5, 11), FeLV was detected. The remaining ten cats were tested negative.

Seven cats were euthanized during surgery. A one-year-old Domestic Shorthair (No. 1) had a survival time of two months and a 13-year-old Siamese (No. 4) survived seven months. Treatment data for these cases were not available.

### 3.1.2. Mast Cell Tumor, n = 1 {#sec3dot1dot2-vetsci-07-00055}

A 16-year-old female British Longhair cat (No. 13) was presented to the clinician for routine vaccination, and during palpation a mass in the abdomen was identified. Ultrasonography showed marked splenomegaly. During laparotomy, a diffusely enlarged (22.0 × 7.5 × 4.0 cm) spleen was removed. Two dark brown masses (0.3 × 0.3 × 0.3 and 1.0 × 0.6 × 0.5 cm) were found within the pancreas. Microscopically they were identified as accessory spleens. Both, spleen and accessory spleens showed marked diffuse infiltration by well-differentiated large mast cells ([Figure 2](#vetsci-07-00055-f002){ref-type="fig"}A). Nuclear atypia and anisokaryosis were mild. The mitotic count was 1/HPF. No vessel infiltration could be observed, but some mast cells infiltrated the mildly hyperplastic pancreatic tissue. Giemsa staining showed intense metachromatic granularity of mast cells ([Figure 2](#vetsci-07-00055-f002){ref-type="fig"}B). However, there was no c-kit expression detectable. FeLV testing was negative. No further treatment was performed. The cat was euthanized 2 months after diagnosis due to progressive renal and cardiac insufficiency.

3.2. Spindle Cell Tumors, n = 4 {#sec3dot2-vetsci-07-00055}
-------------------------------

In two cats (Nos. 14, 15), pancreatic masses were hemangiosarcomas ([Table 2](#vetsci-07-00055-t002){ref-type="table"}). One cat was a 13-year-old Domestic Shorthair (No. 14) with a palpable abdominal mass. Clinical findings in Cat No. 15 were not reported. Blood samples were not investigated in these cases. In both cats, histopathology showed infiltrative vasoformative growth of neoplastic endothelial cells, marked hemorrhage, thrombosis, mixed inflammation, and necrosis in the pancreas ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}A). Mitotic count was 1/HPF and 3/HPF, respectively. The neoplastic cells co-expressed vimentin, vWF and CD31 ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}B). They were tested negative for FeLV. Both cats were euthanized during surgery.

One 17-year-old Domestic Shorthair (No. 16) was lethargic and had a palpable abdominal mass. Pancreas-specific results were within reference intervals, but the SAA value was increased and CBC revealed mild leukocytosis with neutrophilia and lymphopenia ([Table 3](#vetsci-07-00055-t003){ref-type="table"}). Multiple non-encapsulated firm masses (0.1 × 0.1 × 0.1 to 2.0 × 2.0 × 2.0 cm) within the pancreas were noted. Further neoplastic masses were not identified by clinical investigation of the skin or during laparotomy. Microscopically, the multinodular pleomorphic sarcoma with myofibroblastic differentiation was characterized by poorly differentiated spindle cells as well as pleomorphic and multinucleated giant cells within the pancreatic interstitium ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}C). Mitotic count was 9/HPF. Vascular infiltration was present. There were multifocal mild mixed inflammation and small areas of necrosis. The pleomorphic sarcoma showed a diffuse expression of vimentin and inhomogeneous co-expression of actin ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}D). Other sarcomas such as rhabdomyosarcoma, gastrointestinal stromal tumor, or mast cell tumor were excluded by negative immunohistochemical reaction with anti-desmin and c-kit antibodies and Giemsa stain negative. Furthermore, FeLV immunohistochemistry was negative. The cat was euthanized during surgery.

One 13-year-old Domestic Shorthair (No. 17) was presented with poor appetite and ascites. No other intraabdominal masses or cutaneous sarcomas were noted by the clinician. Macroscopically, the submitted tissue samples were brown and firm. Histopathologically, a fibrosarcoma with interstitial infiltrative growth of moderately differentiated neoplastic spindle cells with heterogeneous morphology ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}E) was diagnosed. Mitotic count was 2 mitoses/HPF. Neoplastic cells exclusively expressed vimentin ([Figure 3](#vetsci-07-00055-f003){ref-type="fig"}F). FeLV was negative. The cat was euthanized two weeks after surgery.

4. Discussion {#sec4-vetsci-07-00055}
=============

Pancreatic neoplasms are rare in both humans \[[@B4-vetsci-07-00055]\] and domestic animals \[[@B3-vetsci-07-00055],[@B28-vetsci-07-00055]\]. Epithelial solid and cystic pancreatic neoplasms have been previously described in a larger series of 70 cats \[[@B29-vetsci-07-00055]\]. Non-epithelial neoplasms (e.g., lymphoma, sarcoma) are even rarer in all species \[[@B1-vetsci-07-00055],[@B3-vetsci-07-00055],[@B30-vetsci-07-00055]\].

In general, lymphoma is the most common hematopoietic feline tumor \[[@B31-vetsci-07-00055]\]. A clinical diagnosis of gastrointestinal lymphoma can be challenging because of its unspecific clinical presentation, especially if neither masses nor lymphocytosis are present. During the clinical work up of such uncertain cases, clinical pathology is commonly performed. In our study, cats with lymphoma for which blood values were available (n = 5) showed high (n = 3) or questionable (n = 2) fPLI values, as well as increased DGGR lipase (n = 3) and SAA values (n = 4). This may be explained by an accompanying purulent pancreatitis in four cases. Further studies about pancreas-specific laboratory parameters in cats with lymphomas are necessary to investigate the prevalence of pancreatic involvement. Furthermore, inflammation was also reported in numerous feline epithelial pancreatic tumors \[[@B29-vetsci-07-00055]\] and as far as serological data were available, fPLI value was increased in several cases \[[@B32-vetsci-07-00055]\]. One may conclude that increased serological pancreatic enzymes can be indicative of an acute pancreatitis. However, varying underlying pancreatic neoplasms should be taken into consideration especially if empiric treatment is unsuccessful or if there is imaging evidence of neoplasia. Without histopathological investigation, pancreatic neoplasms may be misdiagnosed as an unsuccessfully treated pancreatitis. However, one cat with T-cell lymphoma (No. 7) showed increased fPLI and DGGR lipase values and normal SAA value without histological signs of pancreatitis. This is consistent with the literature, where false negative (sensitivity) and false positive (specificity) results have been described previously for serological pancreatitis diagnostic in some cases \[[@B33-vetsci-07-00055]\].

Morphological differentiation between inflammatory and neoplastic small lymphocytes in the pancreas may require further investigation. Immunohistochemical assessment is an important diagnostic tool \[[@B34-vetsci-07-00055]\]. In contrast, polymerase chain reaction for antigen receptor gene rearrangement analysis (PARR) is well-known to have some limitations in cats \[[@B35-vetsci-07-00055]\]. In our study, T-cell lymphomas were more frequent (75%) than B-cell lymphomas. This correlates with the adjoining anatomy of small intestine and pancreas as interstitial T-cell lymphomas are more frequent than B-cell lymphomas in cats \[[@B36-vetsci-07-00055]\]. Thus, the pancreatic sites of lymphomas were interpreted as part of a multicentric systemic disease. Immunohistochemistry for FeLV was positive for two cats with T-cell lymphoma (No. 5, 11). This is in accordance with the literature, where retroviral diseases (FeLV or feline immunodeficiency virus) were listed as a risk factor in lymphomas \[[@B14-vetsci-07-00055]\]. In conclusion, without cytological/histopathological examination and/or imaging techniques, feline pancreatic lymphoma is easily missed if solitary pancreatitis is suspected because of clinical pathology and non-specific clinical findings. This has a strong potential impact on therapy and prognosis, especially considering the treatability of lymphomas by chemotherapy. Survival time of lymphoma subtypes may vary. Sato et al. \[[@B37-vetsci-07-00055]\] showed a shorter survival time in alimentary (48 days) lymphomas than in cats with nasal (135 days) or mediastinal (143 days) lymphomas. Wolfesberger et al. \[[@B38-vetsci-07-00055]\] reported the highest survival time in intestinal T-cell lymphomas (1.7 years) compared to large B-cell lymphoma (4.5 months) or peripheral T-cell lymphoma (6.1 months). In our study, seven out of 12 cats with lymphomas were either euthanized or died during or shortly after surgery. Only two cats with lymphomas lived on for 2 months (No. 1, B-cell lymphoma) and 7 months (No. 4, T-cell lymphoma), respectively.

Feline mast cell tumors are predominantly cutaneous neoplasms but can also appear in the spleen \[[@B24-vetsci-07-00055]\]. In our study, a mast cell tumor in accessory splenic tissue was described for the first time. Accessory splenic tissue is usually an incidental finding during laparotomy and appears as small dark brown masses within the pancreas \[[@B39-vetsci-07-00055]\]. Ectopic splenic tissue was seen in 24 out of 540 cases (4%) of routinely submitted feline pancreas samples in our laboratory (unpublished data). As in our case (cat No. 13), a high percentage of mast cell tumors in cats are negative for different immunohistochemical markers, including c-kit \[[@B40-vetsci-07-00055]\], which can impede a diagnosis in poorly differentiated cases. Prognostic factors are not entirely clear in cats, but splenectomy has been recommended for feline splenic mast cell tumors \[[@B41-vetsci-07-00055],[@B42-vetsci-07-00055]\]. Careful exploration of the pancreas is recommended because of the risk of incomplete resection of splenic tissue in the case of affected accessory spleens, as in our case.

Sarcomas of the feline pancreas are very rare. Because of the retrospective nature of our study, there were incomplete data on signalment, therapy, and clinical outcome. Previous clinical and surgical reports were often unavailable. Therefore, a distinction between those sarcomas that were primary pancreatic neoplasms and metastases from elsewhere cannot be made with certainty in all cases. Nevertheless, because of the tumors being exclusively reported within the pancreas, both macroscopically and histologically, there is a high likelihood of them being primaries.

Feline visceral hemangiosarcomas were mostly seen in the liver, intestine, and lymph nodes but rarely (2/26 cats) in the pancreas \[[@B20-vetsci-07-00055]\]. Both cats with hemangiosarcomas included in our study died or were euthanized shortly after surgery. According to the literature, prognosis for feline visceral hemangiosarcoma with a multifocal presentation is poor, with a median survival time of 77 days \[[@B20-vetsci-07-00055]\]. Correlation between the degree of differentiation, mitotic rate or size of feline hemangiosarcoma and the clinical outcome could not be found \[[@B43-vetsci-07-00055]\].

The present study included a fibrosarcoma and a pleomorphic sarcoma in the feline pancreas. Nomenclature of pleomorphic sarcomas is still controversial. The terms "undifferentiated pleomorphic sarcoma," "anaplastic sarcoma with giant cells," or "malignant fibrous histiocytoma" are used synonymously in veterinary pathology \[[@B15-vetsci-07-00055]\]. In cat No. 16, immunohistochemistry revealed small areas of myofibroblastic differentiation within the neoplasm. In literature, this combination of histological type of sarcoma and immunohistochemical expression pattern has been described for feline cutaneous post-vaccinal sarcomas \[[@B44-vetsci-07-00055],[@B45-vetsci-07-00055]\]. Cutaneous sarcomas may undergo malignant transformation of fibrocytes due to an inflammation \[[@B46-vetsci-07-00055]\]. Furthermore, there is one case report of a fibrosarcoma arising at the site of a retained surgical sponge in a cat \[[@B47-vetsci-07-00055]\]. In human medicine, inflammatory pseudotumors have been reported as a benign change in various organs, predominantly in the lungs \[[@B48-vetsci-07-00055]\]. The term "inflammatory fibrosarcoma" was suggested for some of these cases with metastases \[[@B49-vetsci-07-00055]\]. The cat with the pleomorphic sarcoma in our study had increased SAA values of an unknown cause and the pathogenesis of the tumor remained unclear. In human medicine, recurrence of metastatic sarcomas in the pancreas is common and a median overall survival time of 21 months \[[@B17-vetsci-07-00055]\] as well as moderate complication rates \[[@B18-vetsci-07-00055]\] have been described. The cats in our study were euthanized during surgery because of the poor prognosis.

5. Conclusions {#sec5-vetsci-07-00055}
==============

In summary, our study described the characteristics of five different pancreatic tumor types of round or spindle cell origin in 17 cats. It includes the first descriptions of a pancreatic pleomorphic sarcoma and a mast cell tumor in accessory spleens within the pancreas. Epithelial pancreatic neoplasms have been reported previously \[[@B29-vetsci-07-00055]\] and metastases of other carcinomas may affect the pancreas also (unpublished data). In general, pancreatic neoplasms may be accompanied by inflammation, and histopathological investigation is required to differentiate pancreatitis from an inflamed pancreatic neoplasm. This may have a strong impact on therapy and prognosis.
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![(**A**) T-cell lymphoma. The pancreas (P) close to the small intestine (I) is enlarged, white and firm. (16-year-old, male neutered Domestic Shorthair, No. 7, formalin fixed tissue); (**B**) T-cell lymphoma with intense CD3-expression of neoplastic lymphocytes (L) in the pancreas (P). (15-year-old, male neutered Domestic Shorthair, No. 9, IHC, CD3. Bar, 50 µm).](vetsci-07-00055-g001){#vetsci-07-00055-f001}

![(**A**) Mast cell tumor. The accessory spleen is prominent as a mass (S) within the pancreas (P). (16-year-old, female spayed British Longhair, No. 13, HE. Bar, 1000 µm); (**B**) The accessory spleen (S) within the pancreas (P) is diffusely infiltrated by lots of mast cells (the same cat as in (**A**), Giemsa stain. Bar, 25 µm).](vetsci-07-00055-g002){#vetsci-07-00055-f002}

![(**A**) Hemangiosarcoma. Tumor cells form vascular spaces (V) and there is marked inflammation and hemorrhage (H) (12-year-old, female spayed Domestic Shorthair, No. 15. HE. Bar, 100 µm); (**B**) hemangiosarcoma. Intense CD31 expression in neoplastic cells. (same case as (**A**), IHC, CD31. Bar, 25 µm); (**C**) pleomorphic sarcoma. Pleomorphic, poorly differentiated spindle cells with single giant nuclei (arrow) in the pancreas (P) (17-year-old, female Domestic Shorthair, No. 16. HE. Bar, 25 µm); (**D**) pleomorphic sarcoma. Varying expression intensity of smooth muscle actin in pleomorphic tumor cells. (Same case as (**C**) (IHC, actin. Bar, 25 µm); (**E**) fibrosarcoma. Mitotic figures (arrows) and intense anisokaryosis of neoplastic spindle cells between exocrine pancreatic acini (P). (13-year-old, male neutered Domestic Shorthair, No. 17, HE. Bar, 25 µm); (**F**) fibrosarcoma. Intense vimentin expression by the tumor cells (T) infiltrating the pancreas (P) without vimentin expression (same case as (**E**), IHC, vimentin. Bar, 25 µm).](vetsci-07-00055-g003){#vetsci-07-00055-f003}

vetsci-07-00055-t001_Table 1

###### 

Primary antibodies and pretreatment used in immunohistochemistry of 17 feline non-epithelial pancreatic tumors.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker                       Type of Antibody                           Source                                                 Dilution   Pretreatment
  ---------------------------- ------------------------------------------ ------------------------------------------------------ ---------- ---------------------------------
  Vimentin                     Monoclonal mouse\                          Dako, Glostrup, Denmark, M0725                         1:1000     Peroxidase blocking;\
                               anti-vimentin\                                                                                               steam cook in EDTA buffer
                               (Clone V9)                                                                                                   

  Smooth muscle actin          Monoclonal mouse\                          Dako, Glostrup, Denmark, M0851                         1:100      Peroxidase blocking;\
                               anti-human\                                                                                                  pressure cook in citrate buffer
                               (Clone 1A4)                                                                                                  

  Desmin                       Monoclonal mouse\                          Dako, Glostrup, Denmark, M0760                         1:100      Peroxidase blocking;\
                               anti-human\                                                                                                  steam cook in EDTA buffer
                               (Clone D33)                                                                                                  

  Von Willebrand factor        Polyclonal rabbit\                         Dako, Glostrup, Denmark, A0082                         1:2000     Peroxidase blocking;\
                               anti-human                                                                                                   pressure cook in citrate buffer

  CD31                         Monoclonal mouse\                          Dako, Glostrup, Denmark, M0823                         1:100      Peroxidase blocking;\
                               anti-human\                                                                                                  steam cook in EDTA buffer
                               (Clone JC70A)                                                                                                

  CD3                          Monoclonal mouse\                          Dako, Glostrup, Denmark, M7254                         1:100      Peroxidase blocking;\
                               anti-human\                                                                                                  steam cook in EDTA buffer
                               (Clone F7.2.38)                                                                                              

  CD79a                        Monoclonal mouse\                          Bio-Rad Laboratories Inc, Munich, Germany, MCA2538GA   1:3000     Peroxidase blocking;\
                               anti-human\                                                                                                  steam cook in EDTA buffer
                               (Clone HM57)                                                                                                 

  CD117/c-kit                  Polyclonal rabbit\                         Dako, Glostrup, Denmark, A4502                         1:150      Peroxidase blocking;\
                               anti-human                                                                                                   steam cook in EDTA buffer

  Feline Leukemia Virus gp70   Monoclonal mouse\                          Bio-Rad Laboratories Inc, Munich, Germany, MCA1897     1:200      Peroxidase blocking;\
                               anti-feline leukemia virus (Clone C11D8)                                                                     steam cook in EDTA buffer

  Feline Leukemia Virus p27    Monoclonal mouse\                          Bio-Rad Laboratories Inc, Munich, Germany, MCA2551     1:100      Peroxidase blocking;\
                               anti-feline leukemia virus\                                                                                  steam cook in EDTA buffer
                               (Clone PF12J-10A)                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

vetsci-07-00055-t002_Table 2

###### 

Signalment, histopathological/immunohistochemical data and clinical outcome of cats with non-epithelial tumors (n = 17).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case No.   Age (years)   Sex   Breed   Clinical Signs                              Pancreatic Sample Size (cm)                          Diagnosis                        Mi/\   Further Infiltrated Organs                            Staining, IHC Expression   Survival Time   
                                                                                                                                                                           HPF                                                                                                     
  ---------- ------------- ----- ------- ------------------------------------------- ---------------------------------------------------- -------------------------------- ------ ----------------------------------------------------- -------------------------- --------------- ----------
  1          1             MN    DSH     Inappetence, ascites                        TS 0.8 × 0.3 × 0.3                                   Large BCL                        13     Kidney, liver, LN                                     CD79a                      CD3, FeLV       2 months

  2          12            F     SB      Inappetence                                 CM 3.0 × 3.0 × 3.0                                   Large BCL                        5      Om                                                    CD79a                      CD3, FeLV       U

  3 \*       10            MN    BSH     Vomiting, inappetence, palpable abd. mass   CM 4.0 × 4.0 × 4.0                                   Large BCL                        9      Stomach, mAT                                          CD79a                      CD3, FeLV       Eutha

  4          13            MN    Si      Vomiting, diarrhea                          TS 1.0 × 0.4 × 0.3                                   Small TCL                        0      Intestine                                             CD3                        CD79a, FeLV     7 months

  5 \*       15            MN    DSH     Lethargy,\                                  TS 1.5 × 1.5 × 1.5                                   Intermediate TCL                 0      Intestine, mLN                                        CD3, FeLV                  CD79a           Eutha
                                         painful abd.                                                                                                                                                                                                                              

  6          11            F     DSH     Diarrhea                                    TS 0.3 × 0.3 × 0.3                                   Intermediate TCL                 0      \-                                                    CD3                        CD79a           Eutha

  7 \*       16            MN    DSH     Lethargy, ascites                           CP 8.5 × 7.0 × 2.6                                   Intermediate TCL                 3      Intestine, pAT, mLN                                   CD3                        CD79a, FeLV     Eutha

  8          10            MN    DSH     U                                           CP 9.0 × 6.0 × 3.0                                   Intermediate TCL                 4      Liver, intestine, mLN                                 CD3                        CD79a           Eutha

  9 \*       15            MN    DSH     Lethargy, seizures                          CP 7.0 × 6.5 × 0.5 with two masses 0.5 × 0.5 × 0.5   Large TCL                        1      Intestine                                             CD3                        CD79a, FeLV     Eutha

  10         11            M     Cart    U                                           Two TS\                                              Large TCL                        3      Om, spleen                                            CD3                        CD79a, FeLV     Eutha
                                                                                     1.0 × 0.5 × 0.1 and 1.1 × 0.5 × 0.4                                                                                                                                                           

  11         8             FS    DSH     U                                           Two TS\                                              Large TCL                        3      Intestine, mAT                                        CD3, FeLV                  CD79a           U
                                                                                     3.4 × 3.0 × 3.0 and 5.0 × 3.4 × 2.4                                                                                                                                                           

  12 \*      10            MN    DSH     Vomiting,\                                  TS 0.4 × 0.4 × 0.4                                   Large TCL                        4      \-                                                    CD3                        CD79a, FeLV     U
                                         painful abd.                                                                                                                                                                                                                              

  13         16            F     BLH     Palpable abd. mass                          CM 0.3 × 0.3 × 0.3 and 1.0 × 0.6 × 0.5               Mast cell tumor                  1      Spleen                                                Giemsa                     c-kit, FeLV     2 months

  14         13            FS    DSH     Palpable abd. mass                          CM 2.0 × 1.3 × 1.0                                   Hemangio-sarcoma                 3      \-                                                    Vim, vWF, CD31                             Eutha

  15         12            FS    DSH     U                                           TS 5.5 × 2.0 × 0.4                                   Hemangio-sarcoma                 1      Om, intestine, LN                                     Vim, CD31, vWF                             Eutha

  16 \*      17            F     DSH     Palpable abd. mass, lethargy                CP 17.0 × 9.0 × 5.0 with multiple masses up to\      PS with myofibro-blastic parts   9      Om, adherent on capsule of spleen, intestine, liver   Vim, actin                 desmin, c-kit   Eutha
                                                                                     2.0 × 2.0 × 2.0                                                                                                                                                                               

  17         13            MN    DSH     Inappetence, ascites                        Two TS\                                              Fibrosarcoma                     2      Spleen                                                Vim                                        2 weeks
                                                                                     1.2 × 0.8 × 0.6 and 3.0 × 3.0 × 2.0                                                                                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

− = no/negative, + = positive, \* = clinical pathology is available, abd. = abdominal/abdomen, BCL = B-cell lymphoma, BLH = British Longhair, BSH = British Shorthair, Cart = Carthusian, CM = complete mass, CP = complete pancreas, DSH = Domestic Short Hair, Eutha = euthanasia after surgery, F = female, FeLV = feline leukemia virus, F = female spayed, HPF = high power field, IHC = immunohistochemistry, LN = lymph node, M = male, Mi = mitoses, mAT = mesenteric adipose tissue, mLN = mesenteric lymph node, MN = male neutered, Om = omentum, pAT = peripancreatic adipose tissue, PS = pleomorphic sarcoma, SB = Sacred Birman, Si = Siamese, TCL = T-cell lymphoma, TS = tissue sample, U = unknown, Vim = vimentin, vWF = von Willebrand factor.
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###### 

Clinical pathology data of cats with non-epithelial pancreatic tumors (n = 6).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case No.   Diagnosis                       fPLI\           fTLI\            DGGR Lipase (\<26 U/L)   Alpha Amylase (\<1850 U/L)   SAA (\<6.7 µg/mL)   Leuko (6.0--11.0 G/L)   Neutro (3.0--11.0 G/L)   Lymph (1.0--4.0 G/L)
                                             (\<3.5 µg/ L)   (12--82 µg/ L)                                                                                                                              
  ---------- ------------------------------- --------------- ---------------- ------------------------ ---------------------------- ------------------- ----------------------- ------------------------ ----------------------
  3          BCL,\                           4.7             30.7             25.9                     922                          128.83              16.1                    15.0                     0.6
             mild purulent pancreatitis                                                                                                                                                                  

  5          TCL,\                           4.2             25.6             30.1                     552                          41.06                                                                
             mild purulent pancreatitis                                                                                                                                                                  

  9          TCL,\                           5.6             33.0             15.4                     891                          47.51               11.4                    9.2                      1.0
             mild purulent pancreatitis                                                                                                                                                                  

  12         TCL,\                           22.9            43.2             40.6                     839                          62.40                                                                
             mild purulent pancreatitis                                                                                                                                                                  

  7          TCL,\                           \>40.0          14.1             268.7                    405                          4.78                53.1                    31.9                     10.1
             mild lymphocytic pancreatitis                                                                                                                                                               

  16         Pleomorphic sarcoma,\           1.8             38.5             8.7                      701                          86.12               19.3                    18.5                     0.4
             mild mixed pancreatitis                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCL = B-cell lymphoma, DGGR = 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6′-methylresorufin) ester, fPLI = feline pancreatic lipase immunoreactivity, fTLI = feline trypsin-like immunoreactivity, Leuko = leukocytes, Lymph = lymphocytes, Neutro = neutrophilic granulocytes, SAA = serum amyloid A, TCL = T-cell lymphoma.
